Literature DB >> 9850205

London-east Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18 months.

E Kuipers1, D Fowler, P Garety, D Chisholm, D Freeman, G Dunn, P Bebbington, C Hadley.   

Abstract

BACKGROUND: A randomised controlled trial of cognitive-behavioural therapy (CBT) for people with medication-resistant psychosis showed improvements in overall symptomatology after nine months of treatment; good outcome was strongly predicted by a measure of cognitive flexibility concerning delusions. The present paper presents a follow-up evaluation 18 months after baseline.
METHOD: Forty-seven (78% of original n = 60) participants were available for follow-up at 18 months, and were reassessed on all the original outcome measures (see Part I). An economic evaluation was also completed.
RESULTS: Those in the CBT treatment group showed a significant and continuing improvement in Brief Psychiatric Rating Scale scores, whereas the control group did not change from baseline. Delusional distress and the frequency of hallucinations were also significantly reduced in the CBT group. The costs of CBT appear to have been offset by reductions in service utilisation and associated costs during follow-up.
CONCLUSIONS: Improvement in overall symptoms was maintained in the CBT group 18 months after baseline and nine months after intensive therapy was completed. CBT may be a specific and cost-effective intervention in medication-resistant psychosis.

Entities:  

Mesh:

Year:  1998        PMID: 9850205     DOI: 10.1192/bjp.173.1.61

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

Review 1.  Psychosocial treatments for schizophrenia.

Authors:  A S Bellack; S A Brown
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Methodological challenges in studying recurrence of low back pain.

Authors:  Radoslaw Wasiak; Glenn S Pransky; Barbara S Webster
Journal:  J Occup Rehabil       Date:  2003-03

3.  Recent approaches to psychological interventions for people at risk of psychosis.

Authors:  Andreas Bechdolf; Lisa J Phillips; Shona M Francey; Steven Leicester; Anthony P Morrison; Verena Veith; Joachim Klosterkötter; Patrick D McGorry
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-04       Impact factor: 5.270

Review 4.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

5.  Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.

Authors:  Mario Pfammatter; Ulrich Martin Junghan; Hans Dieter Brenner
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

6.  Differentiating the effects of pharmacological and psychosocial interventions in an intensive rehabilitation programme.

Authors:  Andrew Szmidla; Julian Leff
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-07-21       Impact factor: 4.328

7.  Integrating cognitive-behavioral psychotherapy for persons with schizophrenia into a psychiatric rehabilitation program: results of a three year trial.

Authors:  W Bradshaw
Journal:  Community Ment Health J       Date:  2000-10

8.  The interplay of outpatient services and psychiatric hospitalization among Medicaid-enrolled children with autism spectrum disorders.

Authors:  David S Mandell; Ming Xie; Knashawn H Morales; Lindsay Lawer; Megan McCarthy; Steven C Marcus
Journal:  Arch Pediatr Adolesc Med       Date:  2012-01

9.  The Cost-Effectiveness of the Improving Access to Psychological Therapies (IAPT) Programme in Severe Mental Illness: A Decision Analytical Model Using Routine Data.

Authors:  Darshan Zala; Alison Brabban; Alex Stirzaker; Muralikrishnan Radhakrishnan Kartha; Paul McCrone
Journal:  Community Ment Health J       Date:  2019-03-08

Review 10.  The challenge of psychiatric rehabilitation in schizophrenia.

Authors:  S M Glynn
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.